SCHEMBL2072199

SCHEMBL2072199

NC(=O)[C@@H](N)Cc1ccc(Br)nc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 2/20 0.41
CYP11B1 P15538 1/20 0.40
SLC7A5 Q01650 3/20 0.39
CPB2 Q96IY4 2/20 0.37
PTGS1 P23219 2/20 0.37
ALPI P09923 1/20 0.37
PKM P14618 1/20 0.37
XIAP P98170 1/20 0.37
CSK P41240 1/20 0.36
TPH1 P17752 1/20 0.36
FPR2 P25090 1/20 0.36
SCN10A Q9Y5Y9 1/20 0.36
KDM4E B2RXH2 1/20 0.36
USP2 O75604 1/20 0.36
EGFR P00533 1/20 0.36
LCK P06239 1/20 0.36
FYN P06241 1/20 0.36
ADORA3 P0DMS8 1/20 0.36
ALOX15 P16050 1/20 0.36
HTR2A P28223 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2072202 1.00 HSD17B10 (0.41) HSD17B10CYP11B1SLC7A5CPB2PTGS1
SCHEMBL2073432 0.87 HSD17B10 (0.57) HSD17B10SLC7A5CPB2PTGS1ALPI
SCHEMBL2073963 0.87 HSD17B10 (0.57) HSD17B10SLC7A5CPB2PTGS1ALPI
SCHEMBL4200153 0.81 ALDH1A1 (0.45) HSD17B10SLC7A5CPB2CSKPTGS2
SCHEMBL18375252 0.81 SLC7A5 (0.43) HSD17B10SLC7A5CPB2PTGS1ALPI
SCHEMBL20369611 0.81 SLC7A5 (0.43) HSD17B10SLC7A5CPB2PTGS1ALPI
SCHEMBL4072789 0.78 SLC7A5 (0.40) HSD17B10SLC7A5CPB2TDP1
SCHEMBL27805611 0.78 SLC7A5 (0.40) HSD17B10SLC7A5CPB2TDP1
SCHEMBL4053111 0.78 ALDH1A1 (0.41) CYP11B1CPB2FDFT1
SCHEMBL2074876 0.77 HPGDS (0.41)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101945851-B peptidyl nitriles and their use as dipeptidyl peptidase I inhibitors ASTRAZENECA AB 2012-10-31 CN disclosed
US-20110201581-A1 Novel Compounds 010 ASTRAZENECA AB (SE) 2011-08-18 US disclosed
US-20110201581-A1 Novel Compounds 010 ASTRAZENECA AB (SE) 2011-08-18 US disclosed
US-20110201581-A1 Novel Compounds 010 ASTRAZENECA AB (SE) 2011-08-18 US disclosed
US-7902181-B2 Compounds 010 ASTRAZENECA AB (SE) 2011-03-08 US disclosed
US-7902181-B2 Compounds 010 ASTRAZENECA AB (SE) 2011-03-08 US disclosed
US-7902181-B2 Compounds 010 ASTRAZENECA AB (SE) 2011-03-08 US disclosed
CN-101945851-A Peptidyl nitriles and their use as dipeptidyl peptidase I inhibitors ASTRAZENECA AB 2011-01-12 CN disclosed
EP-2231597-A1 PEPTIDYL NITRILES AND USE THEREOF AS DIPEPTIDYL PEPTIDASE I INHIBITORS AstraZeneca AB (SE) 2010-09-29 EP disclosed
US-20090306042-A1 Novel Compounds 010 ASTRAZENECA AB (SE) 2009-12-10 US disclosed
US-20090306042-A1 Novel Compounds 010 ASTRAZENECA AB (SE) 2009-12-10 US disclosed
US-20090306042-A1 Novel Compounds 010 ASTRAZENECA AB (SE) 2009-12-10 US disclosed
WO-2009074829-A1 PEPTIDYL NITRILES AND USE THEREOF AS DIPEPTIDYL PEPTIDASE I INHIBITORS ASTRAZENECA AB (SE) 2009-06-18 WO disclosed
WO-2009074829-A1 PEPTIDYL NITRILES AND USE THEREOF AS DIPEPTIDYL PEPTIDASE I INHIBITORS ASTRAZENECA AB (SE) 2009-06-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090306042-A1 Novel Compounds 010 MRGPRX2, F12, TBXA2R HSD17B10 1448/4885CYP11B1 109/4885SLC7A5 3657/4885
US-20110201581-A1 Novel Compounds 010 MRGPRX2, F12, TBXA2R HSD17B10 1448/4885CYP11B1 109/4885SLC7A5 3657/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.